RATIONALE: Most asthma exacerbations are initiated by viral upper respiratory illnesses. It is unclear whether human rhinovirus (HRV)–induced exacerbations are associated with greater viral replication and neutrophilic inflammation compared with HRV colds. OBJECTIVES: To evaluate viral strain and load in a prospective asthma cohort during a natural cold. METHODS: Adults were enrolled at the first sign of a cold, with daily monitoring of symptoms, medication use, and peak expiratory flow rate until resolution. Serial nasal lavage and induced sputum samples were assessed for viral copy number and inflammatory cell counts. MEASUREMENTS AND MAIN RESULTS: A total of 52 persons with asthma and 14 control subjects without atopy or asthma were studied for over 10 weeks per subject on average; 25 participants developed an asthma exacerbation. Detection of HRVs in the preceding 5 days was the most common attributable exposure related to exacerbation. Compared with other infections, those by a minor group A HRV were 4.4- fold more likely to cause exacerbation (P = 0.038). Overall, sputum neutrophils and the burden of rhinovirus in the lower airway were similar in control subjects without atopy and the asthma group. However, among HRV-infected participants with asthma, exacerbations were associated with greater sputum neutrophil counts (P = 0.005). CONCLUSIONS: HRV infection is a frequent cause of exacerbations in adults with asthma and a cold, and there may be group-specific differences in severity of these events. The absence of large differences in viral burden among groups suggests differential lower airway sensitization to the effects of neutrophilic inflammation in the patients having exacerbations.
RATIONALE: Most asthma exacerbations are initiated by viral upper respiratory illnesses. It is unclear whether human rhinovirus (HRV)–induced exacerbations are associated with greater viral replication and neutrophilic inflammation compared with HRV colds. OBJECTIVES: To evaluate viral strain and load in a prospective asthma cohort during a natural cold. METHODS: Adults were enrolled at the first sign of a cold, with daily monitoring of symptoms, medication use, and peak expiratory flow rate until resolution. Serial nasal lavage and induced sputum samples were assessed for viral copy number and inflammatory cell counts. MEASUREMENTS AND MAIN RESULTS: A total of 52 persons with asthma and 14 control subjects without atopy or asthma were studied for over 10 weeks per subject on average; 25 participants developed an asthma exacerbation. Detection of HRVs in the preceding 5 days was the most common attributable exposure related to exacerbation. Compared with other infections, those by a minor group A HRV were 4.4- fold more likely to cause exacerbation (P = 0.038). Overall, sputum neutrophils and the burden of rhinovirus in the lower airway were similar in control subjects without atopy and the asthma group. However, among HRV-infectedparticipants with asthma, exacerbations were associated with greater sputum neutrophil counts (P = 0.005). CONCLUSIONS:HRV infection is a frequent cause of exacerbations in adults with asthma and a cold, and there may be group-specific differences in severity of these events. The absence of large differences in viral burden among groups suggests differential lower airway sensitization to the effects of neutrophilic inflammation in the patients having exacerbations.
Authors: Anne G Mosser; Rebecca Brockman-Schneider; Svetlana Amineva; Lacinda Burchell; Julie B Sedgwick; William W Busse; James E Gern Journal: J Infect Dis Date: 2002-02-19 Impact factor: 5.226
Authors: Ronald L Sorkness; Guillermo Gonzalez-Fernandez; Erin E Billmeyer; Michael D Evans; James E Gern; Nizar N Jarjour Journal: J Allergy Clin Immunol Date: 2008-09-05 Impact factor: 10.793
Authors: Ellen J Weber; Robert A Silverman; Michael L Callaham; Charles V Pollack; Prescott G Woodruff; Sunday Clark; Carlos A Camargo Journal: Am J Med Date: 2002-10-01 Impact factor: 4.965
Authors: J M Greve; G Davis; A M Meyer; C P Forte; S C Yost; C W Marlor; M E Kamarck; A McClelland Journal: Cell Date: 1989-03-10 Impact factor: 41.582
Authors: J E Tomassini; D Graham; C M DeWitt; D W Lineberger; J A Rodkey; R J Colonno Journal: Proc Natl Acad Sci U S A Date: 1989-07 Impact factor: 11.205
Authors: Jonathan M Corne; Clare Marshall; Sandra Smith; Jacquie Schreiber; Gwendolyn Sanderson; Stephen T Holgate; Sebastian L Johnston Journal: Lancet Date: 2002-03-09 Impact factor: 79.321
Authors: Sameer K Mathur; Paul S Fichtinger; John T Kelly; Wai-Ming Lee; James E Gern; Nizar N Jarjour Journal: Ann Allergy Asthma Immunol Date: 2013-07 Impact factor: 6.347
Authors: Elizabeth A Schwantes; Loren C Denlinger; Michael D Evans; James E Gern; Nizar N Jarjour; Sameer K Mathur Journal: J Allergy Clin Immunol Date: 2015-03-14 Impact factor: 10.793
Authors: Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405